Royalty Pharma plc (RPRX) stock
RPRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 8/3060% above fair value
$69.31+0.34 (+0.49%)
Close on Nov 13, 2026Market cap $39.85BP/E 48.8Yield –
Royalty Pharma operating margin
Operating margin is operating income as a percentage of revenue.
Royalty Pharma's operating margin for the twelve months ending Sep 30, 2026 was 57.1%. For fiscal 2025 it was 65.6%, against 57.1% the year before. The highest annual figure on record is 144.6% in fiscal 2019.
Annual operating margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 65.6% | +8.5 |
| FY2024 | Dec 31, 2024 | 57.1% | −6.3 |
| FY2023 | Dec 31, 2023 | 63.4% | +49.6 |
| FY2022 | Dec 31, 2022 | 13.7% | −48.8 |
| FY2021 | Dec 31, 2021 | 62.5% | −12.7 |
| FY2020 | Dec 31, 2020 | 75.2% | −69.4 |
| FY2019 | Dec 31, 2019 | 144.6% | +68.6 |
| FY2018 | Dec 31, 2018 | 76.0% | – |
Quarterly operating margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | 59.5% | −10.6 |
| Q2 FY2026 | Jun 30, 2026 | 19.7% | −16.5 |
| Q1 FY2026 | Mar 31, 2026 | 89.3% | −4.7 |
| Q4 FY2025 | Dec 31, 2025 | 62.4% | +1.5 |
| Q3 FY2025 | Sep 30, 2025 | 70.1% | −60.1 |
| Q2 FY2025 | Jun 30, 2025 | 36.3% | −13.9 |
| Q1 FY2025 | Mar 31, 2025 | 94.0% | +107.0 |
| Q4 FY2024 | Dec 31, 2024 | 60.9% | −41.9 |
| Q3 FY2024 | Sep 30, 2024 | 130.2% | +101.9 |
| Q2 FY2024 | Jun 30, 2024 | 50.2% | +4.0 |
| Q1 FY2024 | Mar 31, 2024 | -13.0% | −83.0 |
| Q4 FY2023 | Dec 31, 2023 | 102.8% | +188.1 |
| Q3 FY2023 | Sep 30, 2023 | 28.2% | −5.3 |
| Q2 FY2023 | Jun 30, 2023 | 46.2% | −24.3 |
| Q1 FY2023 | Mar 31, 2023 | 70.0% | +30.9 |
| Q4 FY2022 | Dec 31, 2022 | -85.3% | −112.0 |
| Q3 FY2022 | Sep 30, 2022 | 33.5% | −18.2 |
| Q2 FY2022 | Jun 30, 2022 | 70.5% | −63.7 |
| Q1 FY2022 | Mar 31, 2022 | 39.1% | −0.9 |
| Q4 FY2021 | Dec 31, 2021 | 26.6% | −28.2 |
| Q3 FY2021 | Sep 30, 2021 | 51.7% | −43.1 |
| Q2 FY2021 | Jun 30, 2021 | 134.2% | +54.1 |
| Q1 FY2021 | Mar 31, 2021 | 40.0% | −32.1 |
| Q4 FY2020 | Dec 31, 2020 | 54.9% | −236.2 |
| Q3 FY2020 | Sep 30, 2020 | 94.8% | −19.9 |
| Q2 FY2020 | Jun 30, 2020 | 80.1% | +8.5 |
| Q1 FY2020 | Mar 31, 2020 | 72.2% | – |
| Q4 FY2019 | Dec 31, 2019 | 291.1% | – |
| Q3 FY2019 | Sep 30, 2019 | 114.7% | – |
| Q2 FY2019 | Jun 30, 2019 | 71.6% | – |
See a number that looks wrong?